



DATE :
REF :

CONTACT
TÉL.
FAX
E- INFO.BIOCIDES@HEALTH.FGOV.BE
MAIL

HOETMER BV

Nijverheidstraat 12
NL-3316 AP DORDRECHT
Netherlands

SUBJECT **P**rolongation of the authorisation act for product Embalit P (authorisation number BE2012-0036)

Dear Ms, Mr

The CA-May18-Doc.4.1 provides an harmonized approach for renewal of some PT 8 products for which the expiry of the authorisation is the same as the expiry date of the active substance approval. Consequently the current authorisations for products containing propiconazole and/or tebuconazole are prolonged until 28/07/2025. In the same way, the current authorisations for products containing IPBC and/or K-HDO are prolonged until 30/10/2025. For products containing more than one active substance, the relevant date is the one corresponding to the earliest expiry date of any of the contained active substances.

The end date of the authorisation act of your product Embalit P is 31/03/2020. You have already introduced the renewal demand in accordance with provisions stated in CA-May18-Doc 4.1, Art 31 of Regulation 528/2012 and Regulation 492/2014. Since the reference Member State has not yet finalized the renewal procedure for the product, we prolongates the expiry date of authorization of the product Embalit P to 28/07/2025 or until the finalization of the evaluation of the renewal of product by the reference Member State.

This notification is the official prolongation of the authorisation act. All the information stated in the authorisation act is applicable. If the reference Member State finalizes the evaluation of the renewal of the product before the date of 28/07/2025, a new authorisation act will be sent to you, replacing the present one.

Best regards,